Promising phase II trial of new oral treatment for relapsing MS
April 11, 2016The results of a Phase II clinical trial looking at the effects of a new therapy, ozanimod,for relapsing MS has been published in the journal Lancet Neurology. To read more, click on the below link:
Promising phase II trial of new oral treatment for relapsing MS
Article courtesy of MS Research Australia www.msra.org.au